ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
109.87
-2.03 (-1.81%)
At close: Apr 28, 2026, 4:00 PM EDT
110.31
+0.44 (0.40%)
After-hours: Apr 28, 2026, 5:57 PM EDT
ABIVAX Société Anonyme Revenue
In the year 2025, ABIVAX Société Anonyme had annual revenue of 4.57M EUR, down -63.29%. ABIVAX Société Anonyme had revenue of 440.00K in the quarter ending December 31, 2025, a decrease of -89.79%.
Revenue (ttm)
4.57M EUR
Revenue Growth
-63.29%
P/S Ratio
1,651.15
Revenue / Employee
66,232 EUR
Employees
69
Market Cap
8.86B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.57M | -7.88M | -63.29% |
| Dec 31, 2024 | 12.45M | 7.83M | 169.40% |
| Dec 31, 2023 | 4.62M | 38.00K | 0.83% |
| Dec 31, 2022 | 4.58M | -7.38M | -61.68% |
| Dec 31, 2021 | 11.96M | 11.90M | 18,885.71% |
| Dec 31, 2020 | 63.00K | 40.00K | 173.91% |
| Dec 31, 2019 | 23.00K | 5.00K | 27.78% |
| Dec 31, 2018 | 18.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.22B |
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
ABVX News
- 6 days ago - Abivax to Present Data on Obefazimod at Digestive Disease Week® - GlobeNewsWire
- 8 days ago - Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents - GlobeNewsWire
- 21 days ago - This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? - The Motley Fool
- 27 days ago - Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies - GlobeNewsWire
- 4 weeks ago - 2 Healthcare Stocks That Could Soar Over the Next 5 Years - The Motley Fool
- 5 weeks ago - Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears - Benzinga
- 5 weeks ago - Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC - CNBC
- 5 weeks ago - 2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool